本页面由Tiger Trade Technology Pte. Ltd.提供服务

Immix Biopharma, Inc

7.33
-0.1000-1.35%
盘后7.440.1100+1.50%19:41 EST
成交量:98.96万
成交额:731.37万
市值:3.88亿
市盈率:-9.43
高:7.68
开:7.40
低:7.16
收:7.43
52周最高:7.73
52周最低:1.34
股本:5,295.51万
流通股本:4,143.94万
量比:0.92
换手率:2.39%
股息:- -
股息率:- -
每股收益(TTM):-0.7776
每股收益(LYR):-0.7641
净资产收益率:-182.55%
总资产收益率:-66.48%
市净率:46.96
市盈率(LYR):-9.59

数据加载中...

公司资料

公司名字:
Immix Biopharma, Inc
交易所:
NASDAQ
成立时间:
2012
员工人数:
20
公司地址:
11400 West Olympic Boulevard,Suite 200,Los Angeles,California,United States
邮编:
90064
电话:
传真:
- -
简介:
Immix Biopharma, Inc.于2014年1月7日成立为特拉华州公司。公司是一家临床阶段的生物制药公司,专注于嵌合抗原受体细胞疗法(“CAR-T”)在轻链(AL)淀粉样变性和自身免疫性疾病中的应用。公司主导细胞治疗候选药物为美国食品药品监督管理局(“FDA”)研究性新药(“IND”)批准的CAR-T NXC-201,目前正在公司进行的1b/2a期NEXICART-1(NCT04720313)临床试验中进行评估。

董事

名称
职位
Ilya Rachman
Chairman of the Board and Chief Executive Officer
Carey Ng
Independent Director
Gabriel Morris
Chief Financial Officer, Principal Accounting Officer and Director
Helen C. Adams
Independent Director
Jane M. Buchan
Independent Director
Jason Hsu
Independent Director
Magda Marquet
Independent Director
Yekaterina Chudnovsky
Independent Director
Nancy Chang
Director

股东

名称
职位
Ilya Rachman
Chairman of the Board and Chief Executive Officer
Gabriel Morris
Chief Financial Officer, Principal Accounting Officer and Director
Graham Ross
Acting Chief Medical Officer and Head of Clinical Development
Vladimir Torchilin
Scientific Co-Founder